Literature DB >> 18159898

Growth factors and oncogenes as targets in melanoma: lost in translation?

Lawrence Kwong1, Lynda Chin, Stephan N Wagner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18159898      PMCID： PMC2603613          DOI： 10.1016/j.yadr.2007.07.015

Source DB:  PubMed          Journal:  Adv Dermatol        ISSN： 0882-0880


× No keyword cloud information.
  193 in total

1.  Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice.

Authors:  Mingjian James You; Diego H Castrillon; Boris C Bastian; Rónán C O'Hagan; Marcus W Bosenberg; Ramon Parsons; Lynda Chin; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

2.  Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Authors:  N Bardeesy; B C Bastian; A Hezel; D Pinkel; R A DePinho; L Chin
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.

Authors:  A Demunter; M Stas; H Degreef; C De Wolf-Peeters; J J van den Oord
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

4.  PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells.

Authors:  Alexis L Stewart; Abner M Mhashilkar; Xiaohong Helena Yang; Suhendan Ekmekcioglu; Yuji Saito; Kerry Sieger; Robert Schrock; Eric Onishi; Xin Swanson; John B Mumm; Lou Zumstein; Graham J Watson; David Snary; Jack A Roth; Elizabeth A Grimm; Rajagopal Ramesh; Sunil Chada
Journal:  Mol Med       Date:  2002-08       Impact factor: 6.354

5.  Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis.

Authors:  Juan A Recio; Frances P Noonan; Hisashi Takayama; Miriam R Anver; Paul Duray; Walter L Rush; Gerd Lindner; Edward C De Fabo; Ronald A DePinho; Glenn Merlino
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

6.  Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development.

Authors:  G Li; H Schaider; K Satyamoorthy; Y Hanakawa; K Hashimoto; M Herlyn
Journal:  Oncogene       Date:  2001-12-06       Impact factor: 9.867

7.  PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines.

Authors:  P M Pollock; G J Walker; J M Glendening; T Que Noy; N C Bloch; J W Fountain; N K Hayward
Journal:  Melanoma Res       Date:  2002-12       Impact factor: 3.599

8.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

9.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.

Authors:  Harith Rajagopalan; Alberto Bardelli; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Nature       Date:  2002-08-29       Impact factor: 49.962

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962
View more
  7 in total

Review 1.  Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.

Authors:  Holly S Greenwald; Erica B Friedman; Iman Osman
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

2.  Histology-specific microRNA alterations in melanoma.

Authors:  Laura Poliseno; Adele Haimovic; Miguel F Segura; Douglas Hanniford; Paul J Christos; Farbod Darvishian; Jinhua Wang; Richard L Shapiro; Anna C Pavlick; Russell S Berman; Eva Hernando; Jiri Zavadil; Iman Osman
Journal:  J Invest Dermatol       Date:  2012-05-03       Impact factor: 8.551

3.  Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Authors:  Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

4.  RSK1 activation promotes invasion in nodular melanoma.

Authors:  Amel Salhi; Joshua A Farhadian; Keith M Giles; Eleazar Vega-Saenz de Miera; Ines P Silva; Caitlin Bourque; Karen Yeh; Sagar Chhangawala; Jinhua Wang; Fei Ye; David Y Zhang; Eva Hernando-Monge; Yariv Houvras; Iman Osman
Journal:  Am J Pathol       Date:  2015-01-08       Impact factor: 4.307

5.  Genetics and genomics of melanoma.

Authors:  Papia Ghosh; Lynda Chin
Journal:  Expert Rev Dermatol       Date:  2009-04-01

6.  Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.

Authors:  Peng Hou; Dingxie Liu; Meiju Ji; Zhi Liu; James M Engles; Richard L Wahl; Mingzhao Xing
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

7.  The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.

Authors:  Chanh Huynh; Laura Poliseno; Miguel F Segura; Ratna Medicherla; Adele Haimovic; Silvia Menendez; Shulian Shang; Anna Pavlick; Yongzhao Shao; Farbod Darvishian; John F Boylan; Iman Osman; Eva Hernando
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.